Through comprehensive coverage of scientific, business, news, and technology subjects, Drug Development & Delivery provides pharmaceutical professionals with real-world solutions to the issues, opportunities, and challenges shaping the evolving drug development field.
Continued growth in biologics and biosimilars for subcutaneous delivery brings new hurdles, including injection volume, viscosity, and injection time. As a result, the need for high-volume biologics injections (greater than 1mL) subcutaneously is increasing. This trend has driven the rise of safety devices for 2.25mL PFS, which can support large-volume administration, help prevent needlestick injuries, and allow patients to self-administer medications at home. Get the complete story here.